Literature DB >> 21672564

New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice.

Michel Fausther1, Jonathan A Dranoff.   

Abstract

The nuclear bile acid receptor, farnesoid X receptor (FXR), may play a pivotal role in liver fibrosis. We tested the impact of genetic FXR ablation in four different mouse models. Hepatic fibrosis was induced in wild-type and FXR knock-out mice (FXR((-/-))) by CCl(4) intoxication, 3,5-diethoxycarbonyl-1,4-dihydrocollidine feeding, common bile duct ligation, or Schistosoma mansoni (S.m.)-infection. In addition, we determined nuclear receptor expression levels (FXR, pregnane X receptor (PXR), vitamin D receptor, constitutive androstane receptor (CAR), small heterodimer partner (SHP)) in mouse hepatic stellate cells (HSCs), portal myofibroblasts (MFBs), and human HSCs. Cell type-specific FXR protein expression was determined by immunohistochemistry in five mouse models and prototypic human fibrotic liver diseases. Expression of nuclear receptors was much lower in mouse and human HSCs/MFBs compared with total liver expression with the exception of vitamin D receptor. FXR protein was undetectable in mouse and human HSCs and MFBs. FXR loss had no effect in CCl(4)-intoxicated and S.m.-infected mice, but significantly decreased liver fibrosis of the biliary type (common bile duct ligation, 3,5-diethoxycarbonyl-1,4-dihydrocollidine). These data suggest that FXR loss significantly reduces fibrosis of the biliary type, but has no impact on non-cholestatic liver fibrosis. Since there is no FXR expression in HSCs and MFBs in liver fibrosis, our data indicate that these cells may not represent direct therapeutic targets for FXR ligands.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2011        PMID: 21672564      PMCID: PMC3756144          DOI: 10.1016/j.jhep.2011.04.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

Review 1.  Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis.

Authors:  Martin Wagner; Gernot Zollner; Michael Trauner
Journal:  Semin Liver Dis       Date:  2010-04-26       Impact factor: 6.115

Review 2.  Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?

Authors:  James L Boyer
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 3.  Farnesoid X receptor agonists in biliary tract disease.

Authors:  Stefano Fiorucci; Franco Baldelli
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

Review 4.  Portal fibroblasts: Underappreciated mediators of biliary fibrosis.

Authors:  Jonathan A Dranoff; Rebecca G Wells
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

5.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Giovanni Rizzo; Barbara Renga; Andrea Mencarelli; Luisa Riccardi; Stefano Orlandi; Roberto Pellicciari; Antonio Morelli
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium.

Authors:  Nicolas Chignard; Martine Mergey; Véronique Barbu; Laetitia Finzi; Emmanuel Tiret; Annick Paul; Chantal Housset
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

7.  Vectorial transport of bile acids in immortalized mouse bile duct cells.

Authors:  Mami Kida; Yutaka Mano; Yoshiyuki Ueno; Koju Kobayashi; Junichi Goto; Motoyasu Ishii; Toru Shimosegawa
Journal:  Hepatol Res       Date:  2003-10       Impact factor: 4.288

8.  Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.

Authors:  Martin Wagner; Peter Fickert; Gernot Zollner; Andrea Fuchsbichler; Dagmar Silbert; Oleksiy Tsybrovskyy; Kurt Zatloukal; Grace L Guo; John D Schuetz; Frank J Gonzalez; Hanns-Ulrich Marschall; Helmut Denk; Michael Trauner
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

Review 9.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 10.  The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences.

Authors:  Jean-Marc Pascussi; Sabine Gerbal-Chaloin; Cédric Duret; Martine Daujat-Chavanieu; Marie-José Vilarem; Patrick Maurel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

  10 in total
  6 in total

Review 1.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 2.  The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis.

Authors:  Daniel Karin; Yukinori Koyama; David Brenner; Tatiana Kisseleva
Journal:  Differentiation       Date:  2016-08-31       Impact factor: 3.880

Review 3.  Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis.

Authors:  Tongyao Wang; Xingyu Rong; Chao Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

4.  Origin of myofibroblasts in the fibrotic liver in mice.

Authors:  Keiko Iwaisako; Chunyan Jiang; Mingjun Zhang; Min Cong; Thomas Joseph Moore-Morris; Tae Jun Park; Xiao Liu; Jun Xu; Ping Wang; Yong-Han Paik; Fanli Meng; Masataka Asagiri; Lynne A Murray; Alan F Hofmann; Takashi Iida; Christopher K Glass; David A Brenner; Tatiana Kisseleva
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-29       Impact factor: 11.205

Review 5.  The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis.

Authors:  Hiroaki Fuji; Grant Miller; Takahiro Nishio; Yukinori Koyama; Kevin Lam; Vivian Zhang; Rohit Loomba; David Brenner; Tatiana Kisseleva
Journal:  Front Mol Biosci       Date:  2021-12-13

Review 6.  The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.

Authors:  Jun Xu; Xiao Liu; Yukinori Koyama; Ping Wang; Tian Lan; In-Gyu Kim; In H Kim; Hsiao-Yen Ma; Tatiana Kisseleva
Journal:  Front Pharmacol       Date:  2014-07-22       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.